Oncology

Non-Small Cell Lung Cancer Treatment Market Outlook
Novel Insights Into The Non-Small Cell Lung Cancer Market

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of all lung cancers. As per the American Cancer Society, almost 230K new cases were diagnosed in 2022...


Digital Health in the Field of Oncology
Emerging Role of Digital Health in the Field of Oncology

The growth and development in the Digital health technologies, such as mobile health (mHealth) apps, electronic health records (EHRs), electronic medical records (EMRs), wearable devices, teleheal...


bispecific-antibodies
Rise In Bispecific Antibodies Utilization As Antibody Therapeutics

Bispecific Antibodies (BsAbs) are antibodies that contain two different antigens or have two different epitopes on the same antigen. It is observed for Bispecific Antibodies in clinical trials tha...


AACR 2022 KRAS
AACR 2022: Novartis shifting focus towards directly targeting KRASG12c after disappointment from ...

Post Lumakras ‘approval,  Adagrasib’s PDUFA date, Novartis now ready to enter the KRASG12C space Novartis is now heading towards its unique KRASG12C inhibitor in patients with advanced non-smal...


AACR 2022 - LAG 3 Immunotherapy
AACR 2022: LAG-3, one of the most trending Next-generation Immunotherapy

Updates on F-star Therapeutics’ and Akeso’s Bi-specific Antibody targeting LAG-3 and PD-L1 F-star Therapeutics presented the preclinical mechanistic data on the Novel LAG-3 Reduction and Sheddi...


ASCO GU 2022 - Urothelial Carcinoma
Data readout of potential ADCs: Enhertu gears up for Urothelial Carcinoma Market now

Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in Phase Ib study On the second day of ASCO-GU 2022, the rapid abstract session highlighted the r...


PARP Inhibitors in Urothelial Carcinoma
PARP inhibitors in Urothelial carcinoma (UC): Hit or miss?

Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied...


Renal Cell Carcinoma Highlights- ASCO
ASCO GU 2022: Renal Cell Carcinoma Highlights

Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuv...


Bladder Cancer Highlights ASCO
Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder...

Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, a...


Chimeric antigen receptor T cell (CART) Treatment
With early-stage data, Chimeric antigen receptor T cell (CART) finding its way towards entering P...

Use of CAR-T treatments and their efficacy in Prostate Cancer We already know that Immunotherapies have not performed well in the treatment of prostate cancer. Such medicines have failed to eli...